Načítá se...
Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review
Nitric oxide/cyclic guanosine monophosphate (cGMP) signaling is compromised in Alzheimer’s disease (AD), and phosphodiesterase 5 (PDE5), which degrades cGMP, is upregulated. Sildenafil inhibits PDE5 and increases cGMP levels. Integrating previous findings, we determine that most doses of sildenafil...
Uloženo v:
| Vydáno v: | J Alzheimers Dis Rep |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
IOS Press
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7242821/ https://ncbi.nlm.nih.gov/pubmed/32467879 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/ADR-200166 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|